Neurona Therapeutics, a San Francisco, CA-based clinical-stage biotherapeutics company, raised $120M in funding.
The round was led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors, including The Column Group, LYFE Capital, Schroders Capital, Willett Advisors, Ysios Capital Partners, Euclidean Capital, SymBiosis, Alexandria Venture Investments, Berkeley Frontier Fund, Sphera Biotech Master Fund LP, Spur Capital Partners, UCB Ventures, and UC Investments. Raymond Kelleher, M.D., Ph.D., managing director of Cormorant and a neurologist at Massachusetts General Hospital, Harvard Medical School, will be joining the Neurona Board of Directors.
The company intends to use the funds to advance its pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.
Led by Cory R. Nicholas, Ph.D., chief executive officer, Neurona is focused on developing regenerative cell therapy candidates with single-dose curative potential. Its investigational allogeneic, off-the-shelf, cell therapy candidates are designed to provide long-term repair of dysfunctional neural networks for multiple neurological disorders. NRTX-1001 is being evaluated in an ongoing open-label, single-arm Phase I/II clinical trial for treatment of drug-resistant mesial temporal lobe epilepsy (MTLE) and has potential application in Alzheimer’s disease and other disorders of the nervous system.
FinSMEs
09/02/2024